Torasemide

IDI Consulting Joins the Fight Against Heart Disease and Stroke in Pittsburgh

Retrieved on: 
Wednesday, September 7, 2022
Software, General Health, Internet, Professional Services, Philanthropy, Data Management, Technology, Fitness & Nutrition, Fund Raising, Data Analytics, Consulting, Health, Degenerative disease, Research, Commonwealth Place, Canberra, Business process, Ventricular septal defect, Death, American Heart Association, Heart, Systems analysis, Software analysis pattern, Stroke, Project management, Cardiovascular disease, News, Torasemide, Point, Point State Park, Lynch, Health, CPR, IDI, Pharmaceutical industry, Dietary supplement

Join IDI Consulting and other heroes in the community and walk together in the fight against heart disease and stroke.

Key Points: 
  • Join IDI Consulting and other heroes in the community and walk together in the fight against heart disease and stroke.
  • By supporting the 2022 Pittsburgh Heart Walk, IDI Consulting and donors across the country are directly helping the community.
  • Donations to IDI Consultings Heart Walk campaign bring the satisfaction in helping fund the next medical breakthrough in treating heart disease and stroke.
  • Help support IDI Consulting and the American Heart Association in seeing a world free from heart disease and stroke by donating at https://bndfr.com/h4qrd .

Hexion Serves as Start Line Sponsor for 2022 American Heart Association’s Central Ohio Heart Walk

Retrieved on: 
Monday, August 1, 2022
Fund Raising, Professional Services, Philanthropy, Consumer, Cardiology, Other Manufacturing, Health, Other Philanthropy, Chemicals, Plastics, Other Education, Manufacturing, Sustainability, Other Health, Education, Environment, Social Services, Children, American Heart Association, Education, American Heart, Awareness, Science, technology, engineering, and mathematics, Torasemide, CEO, Research, Health, STEM, Degenerative disease, AHA, Columbus metropolitan area, Ohio, Stroke, Hexion, Pharmaceutical industry, Engineering, Technology, Science, Mathematics

As part of its overall efforts to support associate wellness and advocate for healthy communities, Hexion Inc. (Hexion) will serve as the start line sponsor of the American Heart Associations (AHA) Central Ohio Heart Walk on August 20 in downtown Columbus.

Key Points: 
  • As part of its overall efforts to support associate wellness and advocate for healthy communities, Hexion Inc. (Hexion) will serve as the start line sponsor of the American Heart Associations (AHA) Central Ohio Heart Walk on August 20 in downtown Columbus.
  • This is the fourteenth consecutive year that Hexion has sponsored the events start line.
  • Our associates are committed to helping the American Heart Association raise awareness and research funds aimed at preventing heart disease and stroke, said Craig A. Rogerson, Chairman, President and CEO.
  • We are proud to call Columbus our global headquarters and our total support of the Heart Walk over the years has totaled approximately $305,000.

Quidel Corporation and the American Heart Association join forces to Advance Education and Awareness of Heart Disease in San Diego County

Retrieved on: 
Wednesday, June 22, 2022
Technology, Biotechnology, Health, Other Philanthropy, Philanthropy, Research, Medical Devices, Software, General Health, Health Technology, Foundation, Science, Data Management, Cardiology, Degenerative disease, Disability, Cardiovascular disease, Science, Stroke, American Heart Association, Technology, Government, Torasemide, CEO, IVD, Knowledge, Immunoassay, Quidel Corporation, Research, Unitary state, Engineering, Heart failure, AHA, Ortho Clinical Diagnostics, NASDAQ, Health, Quality of life, Volunteering, Nasdaq, American Heart, Death, Twitter, Automation, Transfusion medicine, No, STEM, Friends, Prevalence, Goal, Risk, Organization, Pharmaceutical industry, Dietary supplement, Medical device, Woman, Facebook

Quidel Corporation will invest funding totaling $750,000 and support over the next three years as the American Heart Association approaches their centennial anniversary in 2024.

Key Points: 
  • Quidel Corporation will invest funding totaling $750,000 and support over the next three years as the American Heart Association approaches their centennial anniversary in 2024.
  • Heart disease is the leading cause of death in the U.S., and for many diseases such as heart failure, the prevalence is only increasing.
  • As we remain dedicated to addressing unmet needs in diseases, our top priority continues to be to elevate attention to heart disease.
  • Go Red for Women is the American Heart Associations national movement to increase womens heart health awareness and to improve the lives of women globally.

Solstice Supports the American Heart Association's Broward Heart Walk

Retrieved on: 
Tuesday, March 15, 2022
Sentinel, Torasemide, Nova Southeastern University, Development, Education, GLOBE, American Heart Association, Partnership, Walkers, Inc. (magazine), Mental health, DPPO, Degenerative disease, Solstice, Research, Heart, AHA, Workplace, Pharmaceutical industry, Health insurance, Sun-Sentinel, COVID-19

PLANTATION, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Solstice sponsored the finish line at the American Heart Association (AHA) Broward Heart Walk on Sunday, March 13.

Key Points: 
  • PLANTATION, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Solstice sponsored the finish line at the American Heart Association (AHA) Broward Heart Walk on Sunday, March 13.
  • Our partnership with the AHA's Broward Heart Walk allows us to take our commitment to heart health to the streets literally," said Solstice COO Carlos Ferrera.
  • The team raised over $7,980 for the Broward Heart Walk this year - which will go directly to AHA's research, education efforts, and continued fight against heart disease.
  • The funds raised from the Broward Heart Walk go towards the American Heart Association's work as a relentless force fora world of longer, healthier lives.

Lou Gianquinto, President, Anthem Blue Cross and Blue Shield in Connecticut to Chair New Haven Heart Walk

Retrieved on: 
Wednesday, December 8, 2021
Professional Services, Philanthropy, Health, Insurance, Fitness & Nutrition, Fund Raising, Cardiology, Twitter, Awareness, Risk, Blue Cross Blue Shield Association, Research, Blood pressure, Health, American Heart Association, Torasemide, AHA, Blue Cross (animal charity), Survivor, Volunteering, Death, Industry, Â, Blue, Anthem (company), Disability, American Heart, Multimedia, Missouri, Degenerative disease, Facebook, Blue Cross, Stroke, Walkers, Cardiovascular disease, Walking, Blue Shield, Pharmaceutical industry, the American Heart Association, Anthem Blue Cross and Blue Shield, THE AMERICAN HEART ASSOCIATION, ANTHEM BLUE CROSS AND BLUE SHIELD

View the full release here: https://www.businesswire.com/news/home/20211208005136/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211208005136/en/
    Lou Gianquinto, President, Anthem Blue Cross and Blue Shield in Connecticut to Chair AHA's New Haven Heart Walk (Photo: Business Wire)
    As chair, Gianquinto, originally from West Haven, will lead organizational and recruitment efforts in greater New Haven.
  • COVID-19 hasnt slowed down cardiovascular disease, and awareness about heart healthy living is more crucial than ever, said Lou Gianquinto, president, Anthem Blue Cross and Blue Shield in Connecticut.
  • Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans, Inc. an independent licensee of the Blue Cross Blue Shield Association.
  • The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association.

Advance Auto Parts Raises Nearly $1.7 Million in Support of the American Heart Association®

Retrieved on: 
Tuesday, November 30, 2021
Philanthropy, Automotive, Other Automotive, Automotive Manufacturing, General Automotive, Manufacturing, Fund Raising, AHA, Heart failure, CPR, Achievement, NYSE, Awareness, Triangle, American Heart Association, American Heart, AAP, COVID-19, Torasemide, Research, Advance Auto Parts, Life Is, Degenerative disease, Survivor, Cardiovascular disease, Life, Stroke, Pharmaceutical industry

Advance Auto Parts, Inc. (NYSE: AAP), a leading automotive aftermarket parts retailer, today announced it has raised nearly $1.7 million in support of the American Heart Associations Life is Why campaign.

Key Points: 
  • Advance Auto Parts, Inc. (NYSE: AAP), a leading automotive aftermarket parts retailer, today announced it has raised nearly $1.7 million in support of the American Heart Associations Life is Why campaign.
  • The achievement makes Advance Auto Parts one of the nations largest corporate fundraisers for the American Heart Association.
  • To set another record this year, still in pandemic conditions says a lot about our Advance Auto Parts team members and customers.
  • Advance Auto Parts, Inc. is a leading automotive aftermarket parts provider that serves both professional installer and do-it-yourself customers.

Hexion Serves as Start Line Sponsor for 2021 American Heart Association’s Central Ohio Heart Walk

Retrieved on: 
Tuesday, August 17, 2021
Other Consumer, Chemicals, Plastics, Manufacturing, Cardiology, Philanthropy, Health, Fund Raising, Consumer, Foundation, Degenerative disease, Torasemide, Research, STEM, Health, American Heart, Awareness, CEO, AHA, Education, American Heart Association, Columbus metropolitan area, Ohio, Stroke, COVID-19, Hexion, Science, technology, engineering, and mathematics, Pharmaceutical industry

For the thirteenth consecutive year, Hexion Inc. (Hexion or the Company) will serve as the start line sponsor of the American Heart Associations (AHA) Central Ohio Heart Walk on August 21 in downtown Columbus.

Key Points: 
  • For the thirteenth consecutive year, Hexion Inc. (Hexion or the Company) will serve as the start line sponsor of the American Heart Associations (AHA) Central Ohio Heart Walk on August 21 in downtown Columbus.
  • For 13 consecutive years, Hexion has helped the American Heart Association raise awareness and research funds aimed at preventing heart disease and stroke, said Craig A. Rogerson, Chairman, President and CEO.
  • Over the years, our contributions associated with the Heart Walk have totaled approximately $265,000 and we remain committed to supporting the communities in which our associates live and work.
  • The Heart Walk sponsorship reflects Hexions global commitment to sustainability and corporate social responsibility.

FDA Approves SOAANZ for Edema Treatment in Patients with Heart Failure and Renal Disease

Retrieved on: 
Monday, June 21, 2021
Diuretics, Organs anatomy), Anatomy, Organ failure, Heart diseases, Carbonic anhydrase inhibitors, Heart failure, Loop diuretics, Chronic condition, Torasemide, Metolazone

"Soaanz is specifically formulated to reduce excessive urination in heart failure patients.

Key Points: 
  • "Soaanz is specifically formulated to reduce excessive urination in heart failure patients.
  • "We look forward to launching Soaanz in the next few months, bringing an effective new treatment option to heart failure patients."
  • Soaanz offers an alternative treatment for heart failure patients who skip loop diuretic treatment due to concerns with excessive urination, as well as patients with chronic kidney disease.
  • Loop diuretics are the drug of choice for the treatment of volume overload caused by heart failure and chronic kidney disease.

Sarfez Completes Formulation Development, Plans Clinical Trials for Combination of Loop Diuretic and SGLT-2 Inhibitor

Retrieved on: 
Thursday, September 26, 2019
Chemical compounds, Drugs, Aromatic compounds, RTT, Loop diuretics, Chloroarenes, Carbonic anhydrase inhibitors, Anti-diabetic drugs, SGLT2 inhibitor, Dapagliflozin, Furosemide, Torasemide

The company has completed formulation development work and will begin conducting clinical trials in first quarter of 2020.

Key Points: 
  • The company has completed formulation development work and will begin conducting clinical trials in first quarter of 2020.
  • Sarfez's latest patent application covers the combination of extended release torsemide and an immediate release formulation of a SGLT-2 inhibitor such as dapagliflozin.
  • Torsemide is a high-ceiling loop diuretic with relatively longer half-life and higher but less variable bioavailability compared to the most commonly used loop diuretic, furosemide.
  • Based on these scientific principles, Sarfez Pharmaceuticals has developed a fixed-dose combination of dapagliflozin (SGLT-2 inhibitor) and the company's proprietary formulation of extended release torsemide (loop diuretic) for heart failure treatment.